NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

Mitchell, Paul; Siva, Shankar; Kok, Peey Sei; O'Byrne, Ken; Yeung, Annie; Livingstone, Ann; Donoghoe, Mark; Yip, Sonia; Stockier, Martin R

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

journal contribution

posted on 2024-06-02, 15:11 authored by Paul Mitchell, Shankar Siva, Peey Sei Kok, Ken O'Byrne, Annie Yeung, Ann LivingstoneAnn Livingstone, Mark Donoghoe, Sonia Yip, Martin R Stockier

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

History

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume

15

Pagination

1-1

Location

IL, Chicago

ISSN

0732-183X

eISSN

1527-7755

Language

English

Publication classification

E3.1 Extract of paper

Title of proceedings

Journal of Clinical Oncology

Issue

15_suppl

Publisher

AMER SOC CLINICAL ONCOLOGY

Publication URL

http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps9097

Usage metrics

Keywords

Life Sciences & Biomedicine Oncology Science & Technology

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

History

Journal

Volume

Pagination

Location

ISSN

eISSN

Language

Publication classification

Title of proceedings

Issue

Publisher

Publication URL

Usage metrics

Categories

Keywords

Licence

Exports